drugset / Trial / NCT07665294
Combination CurQD and Vedolizumab in Ulcerative Colitis
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this research study is to test the efficacy and safety of the study intervention, CurQD or placebo (non-active pill), in combination with vedolizumab prescribed as standard of care for patients with ulcerative colitis (UC)..
Timeline
- Start
- 2026-06-24
- Primary completion
- 2027-06-23
- Completion
- 2027-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 235 mg | Oral |
| Subject | Curcumin | Small molecule | 385 mg | Oral |
| Subject | Indigo naturalis | Traditional medicine (herbal / TCM) | 150 mg | Oral |
| Subject | Indigo naturalis | Traditional medicine (herbal / TCM) | 300 mg | Oral |
| Background | Vedolizumab | Monoclonal antibody | — | — |